Literature DB >> 19501693

Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn.

G Ganesh Konduri1, U Olivia Kim.   

Abstract

Rapid evaluation of a neonate who is cyanotic and in respiratory distress is essential for achieving a good outcome. Persistent pulmonary hypertension of the newborn (PPHN) can be a primary cause or a contributing factor to respiratory failure, particularly in neonates born at 34 weeks or more of gestation. PPHN represents a failure of normal postnatal adaptation that occurs at birth in the pulmonary circulation. Rapid advances in therapy in recent years have led to a remarkable decrease in mortality for the affected infants. Infants who survive PPHN are at significant risk for long-term hearing and neurodevelopmental impairments, however. This review focuses on the diagnosis, recent advances in management, and recommendations for the long-term follow-up of infants who have PPHN.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19501693      PMCID: PMC3586568          DOI: 10.1016/j.pcl.2009.04.004

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  114 in total

1.  Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn.

Authors:  J P Kinsella; S R Neish; E Shaffer; S H Abman
Journal:  Lancet       Date:  1992-10-03       Impact factor: 79.321

2.  Increasing oxygen tension dilates fetal pulmonary circulation via endothelium-derived relaxing factor.

Authors:  M H Tiktinsky; F C Morin
Journal:  Am J Physiol       Date:  1993-07

3.  Elevated immunoreactive endothelin-1 levels in newborn infants with persistent pulmonary hypertension.

Authors:  A A Rosenberg; J Kennaugh; S L Koppenhafer; M Loomis; B A Chatfield; S H Abman
Journal:  J Pediatr       Date:  1993-07       Impact factor: 4.406

4.  Inhaled nitric oxide in persistent pulmonary hypertension of the newborn.

Authors:  J D Roberts; D M Polaner; P Lang; W M Zapol
Journal:  Lancet       Date:  1992-10-03       Impact factor: 79.321

5.  Oxygen modulates prostacyclin synthesis in ovine fetal pulmonary arteries by an effect on cyclooxygenase.

Authors:  P W Shaul; W B Campbell; M A Farrar; R R Magness
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

6.  Pulmonary endothelial nitric oxide production is developmentally regulated in the fetus and newborn.

Authors:  P W Shaul; M A Farrar; R R Magness
Journal:  Am J Physiol       Date:  1993-10

7.  Prostaglandin inhibition prevents the fall in pulmonary vascular resistance as a result of rhythmic distension of the lungs in fetal lambs.

Authors:  H Velvis; P Moore; M A Heymann
Journal:  Pediatr Res       Date:  1991-07       Impact factor: 3.756

8.  Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery.

Authors:  A C Chang; A M Atz; G Wernovsky; R P Burke; D L Wessel
Journal:  Crit Care Med       Date:  1995-11       Impact factor: 7.598

Review 9.  Hearing and neurodevelopmental outcome in survivors of persistent pulmonary hypertension of the newborn.

Authors:  M J Marron; M A Crisafi; J M Driscoll; J T Wung; Y T Driscoll; T H Fay; L S James
Journal:  Pediatrics       Date:  1992-09       Impact factor: 7.124

10.  Oxygen modulates nitric oxide production selectively in fetal pulmonary endothelial cells.

Authors:  P W Shaul; L B Wells
Journal:  Am J Respir Cell Mol Biol       Date:  1994-10       Impact factor: 6.914

View more
  33 in total

1.  [Clinicopathological analysis of pulmonary vascular disease in 38 neonates died of respiratory failure].

Authors:  Ning Li; Hong-Wu Chen; Xin-Hua Zhou; Li Liang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2016-04-20

2.  Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn.

Authors:  Krista F Huybrechts; Brian T Bateman; Kristin Palmsten; Rishi J Desai; Elisabetta Patorno; Chandrasekar Gopalakrishnan; Raisa Levin; Helen Mogun; Sonia Hernandez-Diaz
Journal:  JAMA       Date:  2015-06-02       Impact factor: 56.272

Review 3.  B-type natriuretic peptide as a parameter for pulmonary hypertension in children. A systematic review.

Authors:  Chantal A Ten Kate; Dick Tibboel; Ulrike S Kraemer
Journal:  Eur J Pediatr       Date:  2015-08-23       Impact factor: 3.183

4.  A comprehensive study of clinical biomarkers, use of inotropic medications and fluid resuscitation in newborns with persistent pulmonary hypertension.

Authors:  Janardhan Mydam; Marwan Zidan; Nitin Shashikant Chouthai
Journal:  Pediatr Cardiol       Date:  2014-08-09       Impact factor: 1.655

Review 5.  Therapeutic approaches using nitric oxide in infants and children.

Authors:  Robin H Steinhorn
Journal:  Free Radic Biol Med       Date:  2011-01-13       Impact factor: 7.376

6.  Persistent Pulmonary Hypertension of the Newborn.

Authors:  Satyan Lakshminrusimha; Martin Keszler
Journal:  Neoreviews       Date:  2015-12

7.  Hydrocortisone normalizes oxygenation and cGMP regulation in lambs with persistent pulmonary hypertension of the newborn.

Authors:  Marta Perez; Satyan Lakshminrusimha; Stephen Wedgwood; Lyubov Czech; Sylvia F Gugino; James A Russell; Kathryn N Farrow; Robin H Steinhorn
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-12-23       Impact factor: 5.464

8.  Update on PPHN: mechanisms and treatment.

Authors:  Jayasree Nair; Satyan Lakshminrusimha
Journal:  Semin Perinatol       Date:  2014-03       Impact factor: 3.300

9.  Adapted ECMO criteria for newborns with persistent pulmonary hypertension after inhaled nitric oxide and/or high-frequency oscillatory ventilation.

Authors:  Saskia van Berkel; Mathijs Binkhorst; Arno F J van Heijst; Marc H W A Wijnen; Kian D Liem
Journal:  Intensive Care Med       Date:  2013-04-12       Impact factor: 17.440

10.  Impaired cerebral angiogenesis in the fetal lamb model of persistent pulmonary hypertension.

Authors:  Susan S Cohen; Bethany R Powers; Alexandra Lerch-Gaggl; Ru-Jeng Teng; Girija Ganesh Konduri
Journal:  Int J Dev Neurosci       Date:  2014-08-27       Impact factor: 2.457

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.